Clinical trial
A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus
NCT00447213 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 30, 2007
- Completion date
- May 31, 2008
- Enrollment
- 70 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.